Radiation Dose Escalation For Non-Small Cell Lung Cancer Using Hypofractionated 3-Dimensional Conformal Radiation Therapy
- To evaluate the acute and long-term radio-induced toxicity (any organ) of
hypofractionated 3-dimensional conformal radiotherapy in patients with newly diagnosed
stage I-III non-small cell lung cancer.
- To assess the radiological tumor response rate at 3 months after completion of
- To assess the actuarial freedom from thoracic progression rate.
OUTLINE: Patients are stratified according to combined lung volume at 25 Gy (≤ 30% vs >
30%). Patients are assigned to 1 of 3 treatment groups.
- Group 1: Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days
a week for 24 fractions (total of 72 Gy).
- Group 2: Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days
a week for 22 fractions (total of 66 Gy).
- Group 3: Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days
a week for 20 fractions (total of 60 Gy).
After completion of study treatment, patients are followed up every 3 months for 2 years and
then every 6 months thereafter.
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Acute radio-induced toxicity as assessed by the RTOG/EORTC acute toxicity grading system weekly during radiotherapy
weekly during radiotherapy
Pierre Thirion, MD
Saint Luke's Hospital
United States: Federal Government